Lyell Immunopharma, Inc. cotiza a 8.27 USD y tiene una capitalización bursátil de $203M. En los últimos 12 meses ha facturado $27000 con un margen de flujo de caja libre del -418900.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell thera…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.74 | $-1.10 | $-7.68 |
| Estimado | $-1.88 | $-1.79 | $-2.36 | $-2.23 |
| Sorpresa | — | +2.8% | +53.4% | -244.4% |
| Métrica | LYEL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -748344.4% | -38.6% | -748305.8% |
| Net Margin | -762355.6% | -33.6% | -762322.0% |
| FCF Margin | -418900.0% | -13.9% | -418886.1% |
| ROE | -110.6% | -40.4% | -70.2% |
| ROA | -80.7% | -32.0% | -48.7% |
| Current Ratio | 5.28 | 2.84 | +2.44 |
| Debt / Equity | — | 0.28 | — |